Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-Arginine metabolism in mild cognitive impairment subjects converting to alzheimer's disease

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Graham, Stewart F ^a,b   Chevallier, Olivier P ^a   Elliott, Christopher T ^a   Hölscher, Christian ^c   Johnston, Janet ^a   McGuinness, Bernadette ^a   Kehoe, Patrick G ^d   Passmore, Anthony Peter ^a   Green, Brian D ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b William Beaumont Research Institute   (United States)

^c LANCASTER UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETONITRILE; ARGININE; POLYAMINE; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; AMINO ACID METABOLISM; ARTICLE; BLOOD SAMPLING; CHEMOMETRICS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; MASS SPECTROMETRY; METABOLITE; METABOLOMICS; MILD COGNITIVE IMPAIRMENT; POLYAMINE METABOLISM; PROCESS OPTIMIZATION; SENSITIVITY AND SPECIFICITY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; AGED; BLOOD; CASE CONTROL STUDY; COGNITIVE DEFECT; PREDICTIVE VALUE;

AGED; ALZHEIMER DISEASE; ARGININE; BIOMARKERS; CASE-CONTROL STUDIES; COGNITIVE DYSFUNCTION; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; METABOLOMICS; POLYAMINES; PREDICTIVE VALUE OF TESTS;

EID: 84925834088     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119452     Document Type: Article

References (47)

1. Monge-Argiles JA, Munoz-Ruiz C, Pampliega-Perez A, Gomez-Lopez MJ, Sanchez-Paya J, Rodriguez Borja E, et al. Biomarkers of Alzheimer's disease in the cerebrospinal fluid of spanish patients with mild cognitive impairment. Neurochem Res 2011; 36: 986-93. doi: 10.1007/s11064-011-0438-x PMID: 21399907
2. Knight WD, Okello AA, Ryan NS, Turkheimer FE, Rodriguez Martinez de Llano S, Edison P, et al. Car-bon-11-pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain 2011; 134: 293-300. doi: 10.1093/brain/awq310 PMID: 21084313
3. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734-46. PMID: 17616482
4. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256: 183-94. PMID: 15324362
5. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999; 56: 303-8. PMID: 10190820
6. Lopez OL, Kuller LH, Becker JT, Dulberg C, Sweet RA, Gach HM, et al. Incidence of dementia in mild cognitive impairment in the cardiovascular health study cognition study. Arch Neurol 2007; 64: 416-20. PMID: 17353386
7. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia-meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 2009; 119: 252-65. doi: 10.1111/j. 1600-0447.2008.01326.x PMID: 19236314
8. Beckonert O, Keun HC, Ebbels TM, Bundy J, Holmes E, Lindon JC, et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2007; 2: 2692-703. PMID: 18007604
9. Kaddurah-Daouk R, Zhu H, Sharma S, Bogdanov M, Rozen SG, Matson W, et al. Alterations in metabolic pathways and networks in alzheimer's disease. Transl Psychiatry 2013; 3: e244. doi: 10.1038/tp. 2013.18 PMID: 23571809
10. Graham SF, Holscher C, McClean P, Elliott C, Green B. Brain tissue and plasma used to metabolically phenotype alzheimer's disease in APP/PS1 mice. Metabolomics 2013; 9: 974-983.
11. Ibanez C, Simo C, Barupal DK, Fiehn O, Kivipelto M, Cedazo-Minguez A, et al. A new metabolomic workflow for early detection of alzheimer's disease. J Chromatogr A 2013; 1302: 65-71. doi: 10.1016/j. chroma.2013.06.005 PMID: 23827464
12. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98. PMID: 1202204
13. Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. The addenbrooke's cognitive examination revised (ACE-R): A brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 2006; 21: 1078-85. PMID: 16977673
14. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment-beyond controversies, towards a consensus: Report of the international working group on mild cognitive impairment. J Intern Med 2004; 256: 240-6. PMID: 15324367
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on alzheimer's disease. Neurology 1984; 34: 939-44. PMID: 6610841
16. Brandt J, Aretouli E, Neijstrom E, Samek J, Manning K, Albert MS, et al. Selectivity of executive function deficits in mild cognitive impairment. Neuropsychology 2009; 23: 607-18. doi: 10.1037/a0015851 PMID: 19702414
17. Nordlund A, Rolstad S, Klang O, Edman A, Hansen S, Wallin A. Two-year outcome of MCI subtypes and aetiologies in the goteborg MCI study. J Neurol Neurosurg Psychiatry 2010; 81: 541-6. doi: 10. 1136/jnnp.2008.171066 PMID: 19965857
18. Summers MJ, Saunders NL. Neuropsychological measures predict decline to alzheimer's dementia from mild cognitive impairment. Neuropsychology 2012; 26: 498-508. doi: 10.1037/a0028576 PMID: 22612573
19. Graham SF, Chevallier OP, Roberts D, Holscher C, Elliott CT, Green BD. An investigation of the human brain metabolome to identify potential markers for early diagnosis and therapeutic targets of alzheimer's disease. Analytical Chemistry 2012; 85: 1803-11.
20. Zhang A, Zhou X, Zhao H, Guan Y, Zhou S, et al. (2014) Rapidly improved determination of metabolites from biological data sets using the high-efficient TransOmics tool. Mol Biosyst 10: 2160-2165. doi: 10. 1039/c4mb00222a PMID: 24889752
21. Want EJ, Wilson ID, Gika H, Theodoridis G, Plumb RS, Shockcor J, et al. Global metabolic profiling procedures for urine using UPLC-MS. Nat Protoc 2010; 5: 1005-18. doi: 10.1038/nprot.2010.50 PMID: 20448546
22. Tsang TM, Haselden JN, Holmes E. Metabonomic characterization of the 3-nitropropionic acid rat model of huntington's disease. Neurochem Res 2009; 34: 1261-71. doi: 10.1007/s11064-008-9904-5 PMID: 19148750
23. Oresic M, Hyotylainen T, Herukka S, Sysi-Aho M, Mattila I, Seppanan-Laakso T, et al. Metabolome in progression to alzheimer's disease. Translational Psych. 2011, 1: e57
24. Trushina E, Dutta T, Persson XM, Mielke MM, Petersen RC. Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and alzheimer's disease using metabolomics. PLoS One 2013; 8: e63644. doi: 10.1371/journal.pone.0063644 PMID: 23700429
25. Motsinger-Reif A, Zhu H, Kling M, Matson W, Sharma S, Fiehn O, et al. Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating alzheimer's disease from normal cognitive aging. Acta Neuropathologica Communications 2013; 1: 28. doi: 10.1186/2051-5960-1-28 PMID: 24252434
26. Vural H, Sirin B, Yilmaz N, Eren I, Delibas N. The role of arginine-nitric oxide pathway in patients with alzheimer disease. Biol Trace Elem Res 2009; 129: 58-64. doi: 10.1007/s12011-008-8291-8 PMID: 19099206
27. Becker-Catania SG, Gregory TL, Yang Y, Gau CL, de Vellis J, Cederbaum SD, et al. Loss of arginase I results in increased proliferation of neural stem cells. J Neurosci Res 2006; 84: 735-46. PMID: 16773651
28. Maxwell AJ, Anderson B, Zapien MP, Cooke JP. Endothelial dysfunction in hypercholesterolemia is reversed by a nutritional product designed to enhance nitric oxide activity. Cardiovasc Drugs Ther 2000; 14: 309-16. PMID: 10935153
29. Esch F, Lin KI, Hills A, Zaman K, Baraban JM, Chatterjee S, et al. Purification of a multipotent antideath activity from bovine liver and its identification as arginase: Nitric oxide-independent inhibition of neuronal apoptosis. J Neurosci 1998; 18: 4083-95. PMID: 9592089
30. Wallace HM, Fraser AV, Hughes A. A perspective of polyamine metabolism. Biochem J 2003; 376: 1-14. PMID: 13678416
31. Inoue K, Tsutsui H, Akatsu H, Hashizume Y, Matsukawa N, Yamamoto T, et al. Metabolic profiling of Alzheimer's disease brains. Sci Rep 2013; 3: 2364. doi: 10.1038/srep02364 PMID: 23917584
32. Yatin SM, Varadarajan S, Link CD, Butterfield DA. In vitro and in vivo oxidative stress associated with alzheimer's amyloid beta-peptide (1-42). Neurobiol Aging 1999; 20: 325,30; discussion 339-42. PMID: 10588580
33. Yatin SM, Yatin M, Varadarajan S, Ain KB, Butterfield DA. Role of spermine in amyloid beta-peptide-associated free radical-induced neurotoxicity. J Neurosci Res 2001; 63: 395-401. PMID: 11223914
34. Makitie LT, Kanerva K, Polvikoski T, Paetau A, Andersson LC. Brain neurons express ornithine decar-boxylase-activating antizyme inhibitor 2 with accumulation in alzheimer's disease. Brain Pathol 2010; 20: 571-80. doi: 10.1111/j.1750-3639.2009.00334.x PMID: 19832840
35. Rossor MN, Garrett NJ, Johnson AL, Mountjoy CQ, Roth M, Iversen LL. A post-mortem study of the cholinergic and GABA systems in senile dementia. Brain 1982; 105: 313-30. PMID: 7082992
36. Salek RM, Xia J, Innes A, Sweatman BC, Adalbert R, Randle S, et al. A metabolomic study of the CRND8 transgenic mouse model of alzheimer's disease. Neurochem Int 2010; 56: 937-47. doi: 10. 1016/j.neuint.2010.04.001 PMID: 20398713
37. Lalande J, Halley H, Balayssac S, Gilard V, Dejean S, Martino R, et al. 1H NMR metabolomic signatures in five brain regions of the AbetaPPswe Tg2576 mouse model of alzheimer's disease at four ages. J Alzheimers Dis 2014; 39: 121-43. doi: 10.3233/JAD-130023 PMID: 24145382
38. Lowe SL, Francis PT, Procter AW, Palmer AM, Davison AN, Bowden DM. Gamma-Amminobutryic Acid Concentration in Brain Tissue at Two Stages of Alzheimer's disease. Brain 1988; 111: 785-99. PMID: 3401683
39. Gamba P, Testa G, Sottero B, Gargiulo S, Poli G, Leonarduzzi G. The link between altered cholesterol metabolism and alzheimer's disease. Ann N Y Acad Sci 2012; 1259: 54-64. doi: 10.1111/j.1749-6632. 2012.06513.x PMID: 22758637
40. Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of alzheimer's disease. PLoS One 2010; 5: e13950. doi: 10.1371/journal.pone.0013950 PMID: 21085570
41. Kloppenborg RP, van den Berg E, Kappelle LJ, Biessels GJ. Diabetes and other vascular risk factors for dementia: Which factor matters most? A systematic review. Eur J Pharmacol 2008; 585: 97-108. doi: 10.1016/j.ejphar.2008.02.049 PMID: 18395201
42. Li L, Holscher C. Common pathological processes in alzheimer disease and type 2 diabetes: A review. Brain Res Rev 2007; 56: 384-402. PMID: 17920690
43. Crane PK, Walker R, Hubbard RA, Li G, Nathan DM, Zheng H, et al. Glucose levels and risk of dementia. N Engl J Med 2013; 369: 540-8. doi: 10.1056/NEJMoa1215740 PMID: 23924004
44. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for alzheimer's disease: A review of 17 epidemiologic studies. Neurology 1996; 47: 425-32. PMID: 8757015
45. Leoutsakos JM, Muthen BO, Breitner JC, Lyketsos CG, ADAPT Research Team. Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical alzheimer disease: Findings from the randomized controlled alzheimer's disease anti-inflammatory prevention trial. Int J Geriatr Psychiatry 2012; 27: 364-74. doi: 10.1002/gps.2723 PMID: 21560159
46. Xiang Z, Ho L, Yemul S, Zhao Z, Qing W, Pompl P, et al. Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of alzheimer's disease neuropathology. Gene Expr 2002; 10: 271-8. PMID: 12450219
47. Melnikova T, Savonenko A, Wang Q, Liang X, Hand T, Wu L, et al. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Neuroscience 2006; 141: 1149-62. PMID: 16753269